Shin W. Kang

Shin W. Kang, Ph.D. is the Chief Scientific Officer and Head of Research at HCR. Dr. Kang leads HCR’s research efforts as well as sourcing related to universities, research institutions, and inventors. Since Dr. Kang’s arrival in 2015, he has successfully integrated HCR’s research efforts into both the investment and business development processes.

Prior to joining HCR, Dr. Kang served as a vice president of equity research at Wells Fargo Securities covering the biotechnology sector. Previously, Dr. Kang managed technology, intellectual property, and business development at the Mount Sinai School of Medicine.

He holds a Ph.D. in Biological Chemistry/Immunology from the University of California, Los Angeles, an M.B.A. from Columbia Business School, and a B.S. from the University of California, Davis.

Dr. Kang also conducted research at Genentech as a postdoctoral fellow.